Opdivo INN: 'nivolumab' · Start of procedure: 17 September 2016 CHMP Co-Rapporteur Assessment...

download Opdivo INN: 'nivolumab' · Start of procedure: 17 September 2016 CHMP Co-Rapporteur Assessment Report 16 November 2016 CHMP Rapporteur Assessment Report 21 November 2016 PRAC Rapporteur

If you can't read please download the document

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)€¦ · Attachment 1: Product AusPAR Opdivo nivolumab Bristol-Myers Squibb Australia Pty.Ltd. PM-2017-02209-1-4 FINAL 24 January

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)€¦ · Attachment 1: Product AusPAR Opdivo nivolumab Bristol-Myers Squibb Australia Pty.Ltd. PM-2017-02209-1-4 FINAL 24 January

OPDIVO - Medicines.org.au · OPDIVO® (op-DEE-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY Both OPDIVO

OPDIVO - Medicines.org.au · OPDIVO® (op-DEE-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY Both OPDIVO

Opdivo, INN - nivolumab...Assessment report EMA/216066/2016 Page 7/84 2. Scientific discussion 2.1. Introduction Opdivo (nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody

Opdivo, INN - nivolumab...Assessment report EMA/216066/2016 Page 7/84 2. Scientific discussion 2.1. Introduction Opdivo (nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody

Assessment report · The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 March 2015. • The first PRAC Rapporteur Risk Management Plan (RMP) Assessment

Assessment report · The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 March 2015. • The first PRAC Rapporteur Risk Management Plan (RMP) Assessment

D80 assessment report - Overview & D120 LOQ template with ... · Web view89 of 100 Rev. 10.19 corr 1 Rapporteur

D80 assessment report - Overview & D120 LOQ template with ... · Web view89 of 100 Rev. 10.19 corr 1 Rapporteur

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)OPDIVO, as monotherapy, is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)OPDIVO, as monotherapy, is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Keytruda, INN - pembrolizumab · CV Percent coefficient of variation = [standard deviation/mean] x 100 ... Updated CHMP Rapporteur Assessment Report 7 December 2016 Updated PRAC Rapporteur

Keytruda, INN - pembrolizumab · CV Percent coefficient of variation = [standard deviation/mean] x 100 ... Updated CHMP Rapporteur Assessment Report 7 December 2016 Updated PRAC Rapporteur

CHMP ASSESSMENT REPORT FOR DuoCover...Rapporteur: Cristina Sampaio Co-Rapporteur: Pieter Neels Page 3 of 37 1.2 Steps taken for the assessment of the product • The application was

CHMP ASSESSMENT REPORT FOR DuoCover...Rapporteur: Cristina Sampaio Co-Rapporteur: Pieter Neels Page 3 of 37 1.2 Steps taken for the assessment of the product • The application was

AUSTRALIAN PRODUCT INFORMATION OPDIVO …Attachment 1: Product information for AusPAR Opdivo Nivolumab BMS Australia PM-2017-03752-1-4 Final 6 August 2018 This Product information

AUSTRALIAN PRODUCT INFORMATION OPDIVO …Attachment 1: Product information for AusPAR Opdivo Nivolumab BMS Australia PM-2017-03752-1-4 Final 6 August 2018 This Product information

European Medicines Agency | - authorised...submitted on 16 August 2007 their dossier in response to the quality issues raised by the CHMP and EMEA. On 7 September 2007, the Rapporteur

European Medicines Agency | - authorised...submitted on 16 August 2007 their dossier in response to the quality issues raised by the CHMP and EMEA. On 7 September 2007, the Rapporteur

CHMP assessment report - ema.europa.eu · 20 February 2014 . EMA/CHMP/175692/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . DuoResp Spiromax

CHMP assessment report - ema.europa.eu · 20 February 2014 . EMA/CHMP/175692/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . DuoResp Spiromax

YOUR OPDIVO® (nivolumab) ACTION PLAN - The …themelanomanurse.org/wp-content/uploads/2017/07/OPDIVO-MULTIPA… · YOUR OPDIVO® (nivolumab) ACTION PLAN ... taken care of right away.

YOUR OPDIVO® (nivolumab) ACTION PLAN - The …themelanomanurse.org/wp-content/uploads/2017/07/OPDIVO-MULTIPA… · YOUR OPDIVO® (nivolumab) ACTION PLAN ... taken care of right away.

CHMP assessment report - European Medicines Agency€¦ · 22 May 2014 . EMA/CHMP/231450/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Gazyvaro.

CHMP assessment report - European Medicines Agency€¦ · 22 May 2014 . EMA/CHMP/231450/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Gazyvaro.

Assessment report - ema.europa.eu€¦ · CHMP Rapporteur Updated Assessment Report 17 April 2015 Opinion 23 April 2015 . 2. Scientific discussion 2.1. Introduction Invega tablets

Assessment report - ema.europa.eu€¦ · CHMP Rapporteur Updated Assessment Report 17 April 2015 Opinion 23 April 2015 . 2. Scientific discussion 2.1. Introduction Invega tablets

Committee for medicinal products for human use (CHMP) · Committee for medicinal products for human use (CHMP) EMA/CHMP/556731/2019 Page 2/38 Table of contents

Committee for medicinal products for human use (CHMP) · Committee for medicinal products for human use (CHMP) EMA/CHMP/556731/2019 Page 2/38 Table of contents

ALPROLIX, INN-eftrenonacog alfa · The Rapporteur and Co-Rapporteur appointed by the CH MP were: Rapporteur: Andrea Laslop Co-Rapporteur: Concepcion Prieto Yerro • The application

ALPROLIX, INN-eftrenonacog alfa · The Rapporteur and Co-Rapporteur appointed by the CH MP were: Rapporteur: Andrea Laslop Co-Rapporteur: Concepcion Prieto Yerro • The application

Assessment report - European Medicines Agency · March 2016. • The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP

Assessment report - European Medicines Agency · March 2016. • The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP

Assessment Report For Zytiga (abiraterone) Procedure … · Zytiga CHMP assessment report Page 6/78 Rapporteur: Arantxa Sancho-Lopez Co-Rapporteur: Robert James Hemmings The application

Assessment Report For Zytiga (abiraterone) Procedure … · Zytiga CHMP assessment report Page 6/78 Rapporteur: Arantxa Sancho-Lopez Co-Rapporteur: Robert James Hemmings The application

Introductions of the Rapporteur - 45th World Conference on ...barcelona.worldlunghealth.org/updates/body/2014-Union-rapporteur... · Introductions of the Rapporteur . Organizing.

Introductions of the Rapporteur - 45th World Conference on ...barcelona.worldlunghealth.org/updates/body/2014-Union-rapporteur... · Introductions of the Rapporteur . Organizing.

Opdivo® (nivolumab) - Magellan Provider 2 | OPDIVO® (nivolumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

Opdivo® (nivolumab) - Magellan Provider 2 | OPDIVO® (nivolumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval.